Publications by authors named "Angelika Martina Starzer"
Article Synopsis
- Brain metastases (BM) are a critical issue for patients with HER2-positive metastatic breast cancer, necessitating better treatment options; the study examined the effectiveness of the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine.* -
- In the TUXEDO-1 trial involving patients with HER2-positive BC and active BM, the results showed a median progression-free survival (PFS) of 21 months and an overall survival (OS) that had not been reached at 26.5 months of follow-up, indicating positive outcomes for T-DXd.* -
- No new safety concerns emerged throughout the trial, with fatigue being the most reported
Background: DNA methylation profiles have emerged as potential predictors of therapeutic response in various solid tumors.
Objective: This study aimed to analyze the DNA methylation profiles of patients with stage IV metastatic melanoma undergoing first-line immune checkpoint inhibitor treatment and evaluate their correlation with a radiological response according to immune-related Response Evaluation Criteria in Solid Tumors (iRECIST).
Methods: A total of 81 tissue samples from 71 patients with metastatic melanoma (27 female, 44 male) were included in this study.
Article Synopsis
- - The TUXEDO-1 trial tested trastuzumab deruxtecan, an antibody-drug conjugate, on 15 patients with HER2-positive metastatic breast cancer and brain metastases, focusing on its ability to treat brain lesions.
- - Results showed a significant intracranial response rate, with 73.3% of patients achieving a complete or partial response, which exceeded the trial's target of 61%.
- - Safety was consistent with previous findings, and patients maintained their quality of life and cognitive function during treatment, suggesting trastuzumab deruxtecan could be a viable option for managing brain metastases in these patients.
Article Synopsis
- Researchers are seeking biomarkers to predict how well patients with head and neck squamous cell carcinoma (HNSCC) will respond to anti-PD-1 immune checkpoint inhibitors for personalized treatment.
- The study analyzed DNA methylation profiles and inflammatory markers in tumor specimens from 37 patients treated with anti-PD-1 therapy after failing platinum-based chemotherapy across two centers.
- Results indicated that a specific methylation signature can help predict responses to treatment, showing potential as a valuable tool for improving patient outcomes in HNSCC.
Background: Dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab (TP) is a standard therapy of metastatic and localized HER2-positive breast cancer (BC), but its activity in breast cancer brain metastases (BCBM) is unknown.
Methods: Patients with HER2-positive BCBM were identified from the Vienna Brain Metastasis Registry and clinical data including patient characteristics, therapies and overall survival (OS) were obtained. Patients were grouped into 'TP', 'other-HER2-targeted therapy' and 'no-HER2-targeted therapy' according to received first-line systemic therapy after diagnosis of BCBM.
Background: During the COVID-19 outbreak, healthcare professionals (HCP) are at the frontline of clinical management and at increased risk for infection. The SARS-CoV-2 seroprevalence of oncological HCP and their patients has significant implications for oncological care.
Methods: HCP and patients with cancer at the Division of Oncology, Medical University of Vienna were included between 21 March and 4 June and tested for total antibodies against SARS-CoV-2 employing the Roche Elecsys Anti-SARS-CoV-2 immunoassay.